38 results about "Mucosal lesion" patented technology

The invention discloses a traditional Chinese medicine-probiotic combined preparation, a preparation method thereof and application of the traditional Chinese medicine-probiotic combined preparation in gastric mucosal lesion protection. The preparation is composed of a traditional Chinese medicine extract and a bacillus subtilis bacterial suspension, the traditional Chinese medicine extract is prepared from radix codonopsis, rhizoma smilacis glabrae, rhizoma atractylodis macrocephalae, fructus aurantii, radix aucklandiae, bletilla striata, herba ecliptae, radix salviae miltiorrhizae, fructus arctii and fructus psoraleae according to a specific proportion through water decoction, filtration, freeze-drying and mixing with the prepared bacterial suspension. The combined preparation has remarkable protection and treatment effects on gastric mucosal lesion caused by helicobacter pylori infection and ethanol, not only can effectively inhibit the growth of helicobacter pylori, but also can relieve gastric inflammatory response and apoptosis, and the effect of the combined preparation is equivalent to or even better than that of a conventional triple therapy or omeprazole. Meanwhile, the preparation shows synergistic interaction functions of regulating body immunity and maintaining intestinal flora balance, the preparation process is simple and convenient, the safety is high, and the preparation has wide application prospects in preparation of drugs for resisting helicobacter pylori, protecting gastric mucosa and regulating intestinal flora.

The invention provides novel injection type glycerine enema which comprises an injection assembly, and the injection assembly comprises an injection tube, a piston, a push rod, a push block, a nipple, a fixing ring, a sealing ring, a gradually-hardened tube, a cavity, an L-shaped plate, a clamping block, a flexible steel rope, a pull ring, a mounting block and a clamping groove. And a piston is connected to the inner wall of the injection tube in a sliding manner. The gradually-hard tube is inserted into a place where the injection tube is inserted, the push block is pushed to drive the push rod to move, the push rod drives the piston to slide on the injection tube, and liquid medicine is pushed in through the gradually-hard tube, outflow and injection caused by two-time extrusion of common glycerine enema are avoided through one-time injection of 20 ml, two-time mucosa damage is avoided, pollution caused by excrement back-pumping after extrusion is finished is avoided, and the injection efficiency is improved. The pull ring is pulled leftwards, the pull ring drives the clamping block to be separated from the clamping groove through the flexible steel rope, the sealing ring is moved to take down the gradually-hard tube, and the gradually-hard tube is disinfected and cleaned respectively, so that the comfort degree is improved, the rectal mucosa is not prone to being damaged, all liquid medicine can be pushed in in a pushing injection mode, and the liquid medicine is not left and wasted.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

The invention belongs to the technical field of biological medicine, and discloses ovomucoprotein glycopeptide and application thereof. According to the application of the ovomucoprotein glycopeptide in preparing the medicine for preventing or treating the alcohol-induced acute gastric mucosal lesion, the percentage of the gastric mucosal lesion area can be reduced to 1.0% or below when the ovomucoprotein glycopeptide is used for protection. The invention creatively discovers and verifies that the glycopeptide derived from ovomucin has a remarkable protective effect on acute gastric mucosal lesion induced by alcohol. According to the discovery of the application, the application field of the natural active ingredient ovomucin is definitely expanded to the protection of acute gastric mucosal lesion for the first time, the technical problem that efficient and natural gastric mucosal protection ingredients are lacked in the prior art is solved, and a brand-new material basis and a clear direction are provided for developing a novel gastric mucosal protective agent.

The invention relates to the technical field of artificial intelligence, and provides an eosinophilic gastroenteritis typing system and method based on multi-modal data, and the method comprises the steps: obtaining a digestive endoscopy image, an ultrasonic endoscopy image, a CT examination image and clinical manifestation data of a to-be-detected person collected in the same time period; the gastrointestinal mucosa lesion state is recognized through a digestive endoscopy image and is represented by numerical features; identifying the abnormal thickening condition of each film layer structure of the gastrointestinal wall through an ultrasonic endoscope image, and representing the abnormal thickening condition by numerical features; lesion hierarchical distribution is judged through an ultrasonic endoscope image, and numerical feature representation is carried out; determining seroperitoneum and intestinal wall thickening conditions through a CT examination image, and performing numerical characteristic representation on the seroperitoneum and intestinal wall thickening conditions; clinical symptom features are obtained through the clinical manifestation data and are represented by numerical features; generating a feature vector based on multi-modal data by using each numerical value feature representation; and inputting the feature vectors into a dynamic typing prediction model to realize the typing prediction of eosinophilic gastroenteritis, thereby improving the accuracy of auxiliary diagnosis and evaluation.

The invention provides application of hippophae rhamnoides extract in preparation of a product for dispelling the effects of alcohol or preventing and treating visceral organ injury caused by drinking, and belongs to the technical field of biological medicine. The invention provides application of a sea-buckthorn extract or a product containing the sea-buckthorn extract in preparation of a product for dispelling the effects of alcohol or preventing and treating visceral organ injury caused by drinking. The sea-buckthorn extract comprises sea-buckthorn fruit oil, sea-buckthorn seed oil and / or sea-buckthorn fruit pulp. The organ injury comprises alcoholic fatty liver, gastric mucosa injury or duodenum mucosa injury. The hippophae rhamnoides fruit extract (hippophae rhamnoides fruit pulp, hippophae rhamnoides fruit oil and hippophae rhamnoides fruit seed oil) and the hippophae rhamnoides fruit and Chinese wolfberry fruit composite primary pulp provided by the invention have the effects of promoting the repair of gastric mucosa and duodenal mucosa and further enhancing the immunity of gastrointestinal tracts, and can effectively prevent and / or treat gastritis, alcoholic fatty liver and duodenal mucosa injury caused by drinking; the traditional Chinese medicine composition can replace traditional medicine treatment and has the advantages of small side effect, economy, practicability, suitability for long-term administration and good compliance.

The invention provides a hedyotis diffusa extract and a preparation method thereof, the hedyotis diffusa extract is prepared by taking a hedyotis diffusa medicinal material as a raw material, adding a 75-85% ethanol solution for extraction, and filtering; concentrating the filtrate until no alcohol smell exists, precipitating with water, and filtering; separating the filtrate by using macroporous resin, sequentially adding 1.5-2.5 BV of water and 3-4BV of 55-65% ethanol solution for elution, collecting 2BV-3BV sections at the tail end of ethanol eluent, and concentrating to obtain a finished product. The invention further provides application of the oldenlandia diffusa extract in preparation of drugs for preventing and / or treating acute gastric mucosal lesion, gastric ulcer and reflux esophagitis, and particularly, the acute gastric mucosal lesion caused by alcohol or acute alcoholic gastric mucosal lesion and the gastric ulcer caused by excessive gastric secretion are included. In addition, the invention also provides a preparation containing the oldenlandia diffusa extract. The oldenlandia diffusa extract provided by the invention has a better curative effect of resisting acute gastric mucosal lesion, the preparation process is green and environment-friendly, the preparation method is simple, and the oldenlandia diffusa extract is suitable for industrial popularization.

The invention belongs to the field of medicines, and discloses a low-molecular-weight hyaluronic acid composition for inhibiting helicobacter pylori, which is characterized by comprising hyaluronic acid and xanthan gum, the mass ratio of the hyaluronic acid to the xanthan gum is (1-9): 1; the molecular weight of the hyaluronic acid is 1 to 600 kDa; the molecular weight range of the xanthan gum is 200 to 8000 kDa; through the special physicochemical property of the xanthan gum and the special biological property of the low-molecular-weight hyaluronic acid, the composition has strong helicobacter pylori inhibition activity after the xanthan gum and the low-molecular-weight hyaluronic acid are combined, and meanwhile, the composition also has the effects of promoting immunity and promoting gastric mucosal lesion repair. Meanwhile, the invention further discloses application and a preparation of the composition.

The invention belongs to the technical field of medicines, and particularly relates to application of hibiscus (the hibiscus is a plant hibiscus flower and an extract and an active monomer thereof) in preparation of medicines for treating stomach diseases (atrophic gastritis, gastric mucosal lesion and gastric cancer). The invention discloses application of hibiscus syriacus in treatment of gastric diseases. The application comprises at least one of chronic atrophic gastritis treatment, gastric mucosa protection and gastric cancer prevention. In-vitro experiments show that the shrub althea flower extract, shrub althea flower polyphenol, syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-beta-D-glucoside (IV) have obvious antioxidant activity and gastric mucosa protection activity, can obviously reduce the ROS content in ethanol-induced GES-1 cells and the expression of apoptosis marker protein Caspase-3 / Bax, and have a wide application prospect.

The invention discloses a multi-cavity ureter sheathing canal system integrating flushing and pressure monitoring functions, and relates to the technical field of medical instruments, the multi-cavity ureter sheathing canal system is characterized by comprising a sheathing canal main body and a micro-catheter channel, the micro-catheter channel is integrated in the wall of the sheathing canal main body, and the micro-catheter channel is communicated with the sheathing canal main body. The sheathing canal main body is provided with a main working channel penetrating through the sheathing canal main body, and the micro-catheter channel and the main working channel extend in parallel; a flexible ureteroscope is arranged in the main working channel in a penetrating mode, and a lateral suction connector is arranged at the near end of the main working channel and used for being connected with a negative pressure suction device. The near end of the sheath tube body is connected with a ureter sheath base, and a water sealing cap is connected to an opening in the near end of the ureter sheath base. The system can continuously supplement perfusate to the pelvis during negative pressure suction, maintain the shape of the pelvis, avoid mucosal injury and realize real-time and accurate pressure monitoring in an operation, so that the broken stone removal efficiency and the operation safety are remarkably improved.

The invention discloses a PDA (at) Gel (at) GO nano-microcapsule for targeting colitis as well as a preparation method and application of the PDA (at) Gel (at) GO nano-microcapsule, and particularly relates to research on relieving colitis on the basis of a galactosylated carboxymethyl chitosan nano-micelle oral micro-capsule delivery drug system. According to the preparation method, a Gal-N-CMCS / Oridonin (GO) nano-micelle formed by loading Oridonin in a self-assembly manner by taking Gal-N-CMCS as a framework is constructed, then the Gal-N-CMCS / Oridonin (GO) nano-micelle is embedded into gelatin microspheres, and the gelatin microspheres are coated with dopamine to prepare the PDA / Gel / GO nano-microcapsule. Oral delivery and colon targeted release of drugs can be achieved, by inhibiting NLRP3 inflammasome activation and promoting epithelial cell regeneration, DSS-induced colitis and mucosal lesion are effectively relieved, and a new strategy and mechanism basis are provided for oral precise treatment of colitis.

A minimally invasive therapeutic device for single-session ablation of cutaneous and mucosal lesions up to 1 cm in diameter is disclosed. The apparatus comprises an ultra-fine (0.2 mm) titanium micro-needle, guided by integrated impedance sensors to ensure accurate penetration depth, and a compact pulsed steam generator that delivers controllable steam (100–150 °C, 1–3 bar) directly into the lesion base. A built-in microsurgical camera provides real-time visualization of lesion borders, enabling precise alignment and confirmation of complete ablation. Modular tips permit safe access to both skin and cervical mucosa, while an ergonomic needle-height adjustment mechanism ensures targeted treatment of deep-seated tissue without harming surrounding healthy areas. This system overcomes the limitations of cryotherapy, laser ablation, and surgical excision by achieving full thermal desiccation and ashing of abnormal tissue in one session, reducing patient discomfort, lowering recurrence rates, and shortening recovery time.

Provided is a composition comprising microalgae and clay, formulated for ingestion, application to skin, an oral cavity, or administration rectally to a mammal. Also provided is a method of treating a mammal. The method comprises administering the above composition to the mammal.

This utility model relates to the technical field of staining agent preparation equipment, and in particular to a staining agent preparation device for mucosal lesion diagnosis. It includes a placement cylinder and a top cover, and further includes: a disposable inner cylinder, which can slide inside the placement cylinder, and a quick-release positioning unit is provided between the disposable inner cylinder and the placement cylinder; a disposable rotating shaft, with several stirring rods fixed to its outer side, and a rotating unit is provided between the disposable rotating shaft and the top cover; and a liquid outlet pipe, with a B-hole on the lower side of the disposable inner cylinder, and the liquid outlet pipe is fixedly connected to the inner side of the B-hole, and can slide inside the positioning tube. By using a disposable inner cylinder, a disposable rotating shaft, and stirring rods, all of which are disposable items, they can be directly replaced after preparation without cleaning, thus avoiding residue and reducing the probability of cross-contamination, improving the production quality and efficiency of the reagent.

The invention relates to the technical field of probiotics, in particular to application of probiotics (in prevention and treatment of gastric mucosal lesion caused by non-steroidal anti-inflammatory drugs (NSAIDs)). The invention also relates to the application of the probiotics in the regulation of COX-1 and / or COX-2 in the stomach. The probiotics are Lactobacillus gasseri BKR-007, and the probiotics are Lactobacillus gasseri BKR-007. The strain BKR-007 can effectively antagonize damage of NSAIDs to gastric mucosa through a multi-mechanism synergistic effect, and the defense capability of the gastric mucosa is remarkably enhanced. The probiotics provide a novel and effective gastric mucosa protection choice for patients who need to take the medicines for a long time, and have a good clinical application prospect.

The invention relates to the technical field of riemerella anatipestifer detection, and provides a biomarker and a detection method for detecting riemerella anatipestifer, and the biomarker is a host mucosal lesion product generated by induction of specific virulence factors of riemerella anatipestifer after duck infection. Comprising a mucoprotein cracking fragment containing a linear epitope GTTPSPVP, a sialylated sugar chain containing a specific sialic acid modification motif, and a Muc2 degradation peptide fragment. The detection method comprises the following steps: collecting a sample, pretreating, detecting corresponding markers for excrement, respiratory tract lavage fluid and mucous membrane scrape samples by adopting ELISA (Enzyme-Linked Immunosorbent Assay), an immunochromatography test strip and a lectin chip respectively, and judging a result according to a set threshold value. The kit is high in specificity, covers the whole infection period, can realize early and on-site rapid detection, and improves the diagnosis reliability.

A method and device for multimodal imaging of dermal and mucosal lesions. The method includes using at least two imaging modalities from which one is a 3D scan of the lesion, and, additionally providing information on the distance and angulation between scanning device and the dermis or mucosa and mapping at least the second modality over the 3D data.

This invention relates to the application of Lactobacillus acidophilus CL-01 in the preparation of products for relieving pollen-induced allergic rhinitis; the CL-01 strain is Lactobacillus acidophilus with accession number GDMCC No:64731. Lactobacillus acidophilus CL-01 strain. This invention develops a new use for Lactobacillus acidophilus CL-01, providing a research basis for its widespread application. It also develops a novel strategy for alleviating pollen-induced allergic rhinitis. This invention finds that Lactobacillus acidophilus CL-01 has a very significant effect in alleviating symptoms related to pollen-induced allergic rhinitis, specifically by significantly improving symptoms such as nasal mucosal lesions, nasal itching, sneezing, runny nose, asthma, and intestinal flora imbalance caused by pollen-induced allergic rhinitis.

The invention belongs to the technical field of biological medicine, and particularly relates to PDRN, a preparation method and application of the PDRN in ulcerative colitis. The PDRN preparation method comprises the following steps: adding salmon sperms into a solvent, crushing to obtain a solid-liquid mixture, centrifuging, collecting precipitate, adding a mixed salt solution, and reacting to obtain a reaction solution; adding a compound enzyme into the reaction liquid, and performing enzymolysis to obtain enzymatic hydrolysate; and removing residual impurities after enzymolysis, carrying out alcohol precipitation, collecting the precipitate, washing the precipitate, centrifuging, collecting the precipitate, crushing the precipitate, and freeze-drying to obtain the PDRN. The PDRN provided by the invention has no cytotoxicity, and can significantly inhibit JAK / STAT and NF [kappa] B inflammation signal pathways and reduce the level of proinflammatory factors; the traditional Chinese medicine composition can improve weight loss, colon shortening, mucosal lesion and other symptoms caused by ulcerative colitis, reduce histological score and inflammatory cell infiltration, and play a synergistic treatment role by adjusting the diversity of intestinal flora.

The invention relates to the technical field of laying hen breeding feed, particularly discloses a feed additive for improving salpingitis and eggshell quality of laying hens in the later egg laying period and application of the feed additive, and aims to relieve the salpingitis of the laying hens in the later egg laying period and improve production performance and egg quality. The technical key points are as follows: when 200 mg / kg of ME or an equal amount of Rottlerin is added into the feed, mucosal lesion and inflammatory cell infiltration caused by salpingitis can be effectively relieved; specifically, swelling and bleeding of the fallopian tube are relieved, epithelial resistance of mucous membranes is improved, expression of tight junction protein is increased, and the level of inflammatory factors is reduced, so that the pathological state of the fallopian tube is remarkably improved; meanwhile, the additive significantly improves the laying rate and egg quality of the laying hens, especially the ultrastructure and strength of eggshells, reduces the feed-egg ratio, and optimizes the production performance of the laying hens. The additive disclosed by the invention can relieve inflammatory response, improve the health level of laying hens and reduce the use of medicines to a certain extent, so that the safe production of the laying hens is guaranteed, and the additive has important application value.

The invention relates to the technical field of veterinary drugs, and particularly discloses a traditional Chinese medicine oral liquid preparation for treating diarrhea syndrome of newborn livestock and a preparation method thereof. The traditional Chinese medicine oral liquid preparation takes stenoloma chusanum, Chinese ilex leaves and liquorice as raw materials to prepare traditional Chinese medicine liquid, and then functional bacterial powder is added and mixed to prepare the oral liquid. According to the preparation, through the synergistic effect of traditional Chinese medicines and bacterial powder, core causes such as pathogenic bacterium infection, intestinal flora imbalance, mucosal lesion and low immunity of newborn livestock and poultry diarrhea are precisely targeted, rapid diarrhea checking is achieved, the cure rate is remarkably increased, and the recurrence rate is reduced; meanwhile, intestinal barriers are repaired, the body resistance is enhanced, nutrient absorption and post-disease growth are promoted, residues are avoided, drug resistance is avoided, the feed is adaptive to physiological characteristics of newborn livestock and poultry, and the resistance reducing requirement of green breeding is met.

The invention belongs to the technical field of traditional Chinese medicines, mainly relates to a traditional Chinese medicine composition and a preparation method thereof, and in particular relates to a traditional Chinese medicine composition for treating liver diseases as well as a preparation method and application thereof. According to the traditional Chinese medicine composition, oldenlandia diffusa, schisandra chinensis, radix pseudostellariae, lucid ganoderma and liquorice are selected, the performance is improved through staged fermentation of lactobacillus rhamnosus CICC-6133 and bifidobacterium breve CICC-6182, then water extraction, concentration and drying are conducted, and the traditional Chinese medicine composition is prepared, and the prepared traditional Chinese medicine composition has the improvement effect on alcoholic fatty liver, hepatitis B, gastric mucosal injury, cirrhosis ascites and advanced liver cancer.

The present disclosure provides systems, kits, and methods for preparation prior to colonoscopy or other colon-related gastrointestinal procedures. In particular, the present invention provides a drug delivery system for gut cleansing products and procedures. The drug delivery system includes a capsule or tablet assembly that can be loaded with salts and other related drugs for use in gut cleansing products and still floats in the stomach after ingestion due to a density of 1.004 gm / ml or less. The drug delivery system avoids mass aggregation of salt near the gastric mucosa during the disintegration phase, thereby reducing the risk of direct gastric mucosal damage that may occur by solid enteral cleansing products.

The present invention relates to a topical composition comprising: a) 0.25% w / w to 1.5% w / w of hyaluronic acid or a salt thereof; b) from 0.01% w / w to 25% w / w of one or more adhesives; and c) from 0.005% w / w to 0.5% w / w of a non-absorbent antibiotic. The invention also relates to a delivery device comprising this composition and its use in medicine, in particular for the treatment and / or prevention of mucosal lesions; the traditional Chinese medicine composition is used for preventing polyp resection syndromes; the medicine is used as an adjuvant therapy for mechanical therapy in alimentary canal perforation; and as a sealant treatment for surgical anastomosis, leaks or fistula of the digestive tract.

The invention discloses a preparation method and application of elaeagnus angustifolia gum water-soluble homogeneous polysaccharide. According to the method, elaeagnus angustifolia gum is taken as a raw material, and the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide is prepared through extraction, ethanol precipitation, separation and purification. Experiments show that the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide reduces disease activity indexes and improves clinical symptoms by restoring body weight and excrement viscosity and reducing intestinal bleeding; the intestinal tract damaged by inflammation is relieved by repairing the mucosal barrier function of the colon tissue; by inhibiting mucosal lesion and remodeling an intestinal flora structure, dysbacteriosis induced by dextran sodium sulfate is reversed, and overall structure damage, mucosal lesion and colon tissue inflammation infiltration of DSS mice are effectively relieved. The application potential of the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide in treatment of ulcerative colitis is disclosed, and the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide is successfully endowed to the field of modern medicine from traditional application. Experimental research not only verifies the effectiveness of the compound, but also provides a new strategy and direct evidence for developing a novel and safe ulcerative colitis therapy derived from natural products, and has a clear application prospect.

The present invention belongs to the field of medicine, and specifically relates to the use of a Cistanche deserticola extract in the preparation of a medicament having a gastric mucosal protective effect and preventing or treating gastric mucosal damage or gastric ulcers. Experimental results show that a Cistanche deserticola extract including total glycosides from Cistanche tubulosa or desert Cistanche deserticola, polysaccharides from Cistanche tubulosa or desert Cistanche deserticola, and oligosaccharides from Cistanche tubulosa or desert Cistanche deserticola, as well as monomeric compounds including salidroside, verbascoside, 2'-acetylverascoside, tubuloside A, echinacoside, and isovarascoside, all have significant gastric mucosal protective effects. The present invention has the prospect of being developed into a medicament having a gastric mucosal protective effect and preventing or treating gastric mucosal damage and gastric ulcers, and has important clinical significance and commercial value.

The invention discloses a sputum suction tube side hole anti-mucosa safety head which comprises a safety head body, the safety head body comprises a tube body and a probe, the probe is movably installed at the head end of the tube body, the tail end of the tube body is provided with a negative pressure device connector, and a gap exists between the probe and the tube body to form an annular side suction hole; a connecting bridge is fixedly connected between the tube body and the probe, the connecting bridge is located in the annular side suction hole, the annular side suction hole is formed to replace a traditional discrete side hole, negative pressure can be dispersed, mucosa damage caused by too large single-point adsorption force is avoided, primary protection is actively pushed away from a mucosa through deformation of the connecting bridge, and the mucosa is prevented from being damaged. The secondary protection is automatically opened through a standby hole to eliminate negative pressure, and the double mechanism ensures that the mucosa can be effectively protected under different adsorption strengths.

This invention relates to the use of Streptococcus thermophilus CT-02 in the preparation of products for relieving pollen-induced allergic rhinitis; the CT-02 strain is Streptococcus thermophilus with accession number GDMCC No:64474. Streptococcus thermophilus CT-02 strain. This invention develops a new use for Streptococcus thermophilus CT-02, providing a research basis for its widespread application. It also develops a novel strategy for alleviating pollen-induced allergic rhinitis. This invention finds that Streptococcus thermophilus CT-02 has a very significant effect in alleviating symptoms related to pollen-induced allergic rhinitis, specifically by significantly improving symptoms such as nasal mucosal lesions, nasal itching, sneezing, runny nose, asthma, and intestinal flora imbalance caused by pollen-induced allergic rhinitis.

It relates to a topical composition comprising a) from 0.25 to 1.5% w / w of a hyaluronic acid or a salt thereof, b) from 0.01 to 25% w / w of one or more adhesive agents, and c) from 0.005 to 0.5% w / w of a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and / or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.